|
BioPharma Credit PLC - specialist life sciences debt investment trust - Enters into a senior secured loan deal with biopharmaceutical company BioCryst Pharmaceuticals Inc through its fully owned subsidiary, together with BioPharma Credit Investments V LP. Says will invest up to $180.0 million and BioPharma-V to invest up to an additional $270.0 million in parallel, with BioPharma Credit acting as collateral agent. Under the terms of the transaction, BioPharma Credit says $120.0 million of $180.0 million is drawn at closing in the first tranche and up to an additional $60.0 million may be drawn by September 30. Says the loan will mature in April 2028. BioCryst currently markets Orladeyo, or called berotralstat, a treatment to prevent attacks of hereditary angioedema in adults and children 12 years of age and older. For 2022, Orladeyo net sales were $251.6 million. Current stock price: $0.97, up 1.0% on Wednesday morning in London 12-month change: down 4.2% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
